TB-500: identity matters

What is TB-500?

The TB-500 identity evaluated by FDA is a synthetic seven-amino-acid fragment of thymosin beta-4 with an acetyl group. It is not the complete parent protein. FDA also identified naming and characterization problems in the material submitted for evaluation.^[1]

TB-500 and thymosin beta-4 are different

Online discussions sometimes move between TB-500, thymosin beta-4 and related fragments without explaining the difference. That makes a claim difficult to assess. Ask for the ingredient name in the study and in the proposed pharmacy product, not just the familiar marketing name.

Clinical results involving the parent molecule cannot be transferred to a fragment by name association. A different sequence, formulation or route can change how a substance behaves. The October HHS appendix discusses evidence concerning both identity and the parent molecule; this does not make every related product interchangeable.^[1][2]

What does the recovery research mean?

In its July 2026 evaluation, FDA did not identify direct clinical studies supporting TB-500 for wound healing in people. That finding describes the evidence reviewed at that time. HHS later described additional utilization and characterization information in its October appendix. Neither document establishes a proven benefit for every recovery claim made online.^[1][2]

A strong recovery study would measure outcomes that matter to patients, compare appropriate care plans and account for rehabilitation and other treatment. Testimonials and before-and-after stories cannot reliably do that.

What remains uncertain about safety?

FDA identified uncertainty about immune reactions, aggregation and impurities, as well as gaps in direct human safety information for the fragment. Lack of adequate information is different from evidence that a product is harmless.^[1]

Quality questions include whether the ingredient identity is confirmed, what lot-specific testing covers and whether the finished product is appropriate for its intended route. Discuss these with the prescribing clinician and dispensing pharmacy, along with how progress and adverse effects would be followed.

U.S. compounding access

The October HHS appendix describes TB-500 acetate for specified injectable routes under conditional enforcement discretion. The accompanying published notice calls the policy draft and nonbinding. It does not turn a compounded TB-500 product into an FDA-approved medication.^[2][3]

What to discuss before considering it

Describe the injury, when it started, any examination or imaging, and what has helped so far. Ask whether rehabilitation, an established treatment or specialist review should come first. Agree on the expected outcome and follow-up plan before discussing an additional compound.

A combination containing BPC-157 and TB-500 needs its own evaluation. Separate research on two substances does not establish the benefit or safety of combining them. The October policy specifies single-active-ingredient products.^[2]

Common questions about TB-500

Sources and context

1. FDA scientific briefing: TB-500 (July 2026)Historical staff evaluation for advisory-committee discussion. Read alongside the later HHS access policy, not as a current prohibition.
2. HHS peptide compounding policy and Appendix B (October 2026)Conditional enforcement-discretion policy, including specified ingredient identities and routes.
3. Published Federal Register notice, October 30, 2026Describes the policy as draft and nonbinding. Compounded drugs are not FDA-approved.